Health Minister Greg Hunt even went so far as to say that the government would like Australia to one day be “the world’s number one medicinal cannabis supplier”.With pronouncements like that – from the Federal Government no less – it’s no wonder local investors have been desperate to put their money into Australia’s pot stocks. Krista has led transactions with deal values ranging from $20,000 to $4.5 billion across multiple sectors advising a diverse base of private and listed companies, private equity funds, governments and individuals, nationally and internationally. Susan has over 20 years’ experience in the corporate finance industry. Quentin has also held non-executive director roles within several companies. Prior to Canopy Growth, Marcel was Director of Cannabinoid Research for Zynerba Pharmaceuticals, a leading transdermal cannabinoid pharmaceutical company.Bruce is a highly experienced senior executive and independent company director with a background in the life sciences industry focussed on finance, operations, governance, business and investment management, and strategic planning.In addition to AusCann, Bruce is a non-executive director of Adherium Limited, an ASX listed digital health technology company and he is a Special Adviser to BioScience Managers Pty Ltd, an international healthcare investment firm that finances and enables innovative science and technology with the potential to transform healthcare.Bruce previously served as the Chief Financial Officer, Director of Operations and Director of Strategic Projects with the Telethon Kids Institute in Western Australia. She has over ten years’ experience, and has held several senior roles, in research and development management, with a focus on governance frameworks and operational processes, including the development of bespoke research management systems, contractual frameworks and risk assessment of research activities, including clinical trials. AusCann is an Australian-based pharmaceutical company focused on the development, production, and distribution of cannabinoid-based medicines within Australia and internationally.
... including acquisition or investment in other international plant breeders, producers and suppliers. Aussie pot stocks have been on a tear. But before you throw your life-savings away it’s important to remember that, despite the skyrocketing share prices, most of these companies are still in their infancy, are yet to generate any substantive revenue, and are very high risk investments.It’s probable that not all of them will survive the next few years – let alone ever turn a profit.Auscann’s board is led by founding Chairman Dr Mal Washer, a medical doctor and former member of the Australian House of Representatives, and also includes Hon Cheryl Edwardes, the former Attorney-General for Western Australia and former Minister for the Environment. His experience covers a comprehensive range of healthcare technologies and commercial strategies: from capsules and inhalers to innovative biologics and digital health solutions.Max is a highly regarded health care industry director with a broad range of executive and pharmaceutical experience. The Motley Fool Australia operates under AFSL 400691. Simply Wall St. ... it seems that the company is ratcheting up investment … For more information please see our The Motley Fool Australia, PO Box 4635, Ashmore, Qld 4214Rhys Brock has been a Motley Fool contributor since late 2017. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to …